Stock Price
P/E Ratio
Volume Traded Today
Dividend
52 Week High/low
TG Therapeutics Inc Market Cap
Based on ratings from 10 stock analysts, the TG Therapeutics Inc stock price is expected to increase by 11.11% in 12 months. This is calculated by using the average 12-month stock price forecast for TG Therapeutics Inc. The lowest target is $9 and the highest is $55. Please note analyst price targets are not guaranteed and could be missed completely.
About 10 Wall Street analysts have assignedTGTX 8 buy ratings, 1 hold ratings, and 1 sell ratings. This means that analysts expect TG Therapeutics Inc to buy. Keep in mind that these ratings are typically refreshed every quarter, underscoring the importance of conducting your own research on TGTX. Don't forget to include both technical and fundamental analysis, as well as staying informed on news that could influence these ratings, in your due diligence.
These are the latest 20 analyst ratings of TGTX.
|
Analyst/Firm |
Rating |
Price Target |
Change |
Date |
|---|---|---|---|---|
| Eric Joseph JP Morgan | Overweight | $43 | Maintains | Nov 25, 2024 |
| Corinne Jenkins Goldman Sachs | Neutral | $22 | Maintains | Nov 5, 2024 |
| Edward White HC Wainwright & Co. | Buy | $55 | Maintains | Nov 5, 2024 |
| Tara Bancroft TD Cowen | Buy | $50 | Initiates | Oct 29, 2024 |
| Edward White HC Wainwright & Co. | Buy | $49 | Reiterates | Sep 18, 2024 |
| Mayank Mamtani B. Riley Securities | Buy | $34 | Maintains | Aug 7, 2024 |
| Corinne Jenkins Goldman Sachs | Neutral | $20 | Maintains | Aug 7, 2024 |
| Edward White HC Wainwright & Co. | Buy | $49 | Reiterates | Aug 6, 2024 |
| Matthew Kaplan Ladenburg Thalmann | Buy | $40 | Maintains | May 2, 2024 |
| Edward White HC Wainwright & Co. | Buy | $49 | Maintains | May 2, 2024 |
| Eric Joseph JP Morgan | Overweight | $25 | Reiterates | Apr 18, 2024 |
| Matthew Kaplan Ladenburg Thalmann | Buy | $39 | Reiterates | Apr 18, 2024 |
| Edward White HC Wainwright & Co. | Buy | $45 | Reiterates | Apr 18, 2024 |
| Edward White HC Wainwright & Co. | Buy | $45 | Reiterates | Mar 1, 2024 |
| Corinne Jenkins Goldman Sachs | Neutral | $13 | Maintains | Feb 29, 2024 |
| Edward White HC Wainwright & Co. | Buy | $45 | Reiterates | Feb 28, 2024 |
| Mayank Mamtani B. Riley Securities | Buy | $29 | Maintains | Feb 5, 2024 |
| Edward White HC Wainwright & Co. | Buy | $45 | Maintains | Jan 11, 2024 |
| Eric Joseph JP Morgan | Overweight | $23 | Maintains | Nov 1, 2023 |
| Matthew Andrews Jefferies | Buy | Maintains | Nov 1, 2023 |
When did it IPO
2010
Staff Count
319
Country
United States
Sector/Industry
Healthcare/Biotechnology
CEO
Mr. Michael S. Weiss Esq.
Market Cap
$5.45B
In 2023, TGTX generated $233.7M in revenue, which was a increase of 0.00% from the previous year. This can be seen as a signal that TGTX's business is growing, and its share price could be worth more in the future. However, if the company grows faster (or slower) than expected, this could also have a major impact on the future share price.
Revenue From 2020
Revenue From 2021
Revenue From 2022
Revenue From 2023
Thu, 21 Nov 2024
Sentiment - NEUTRAL
Source - GlobeNewsWire
Summary - TG Therapeutics, Inc. (NASDAQ: TGTX) ranked first on the Deloitte Technology Fast 500™, highlighting its status as a leading fast-growing company in North America.
Why It Matters - TG Therapeutics' top ranking in the Deloitte Technology Fast 500 highlights its rapid growth, potentially increasing investor confidence and interest, which can drive stock prices higher.
Tue, 05 Nov 2024
Sentiment - POSITIVE
Source - Seeking Alpha
Summary - TG Therapeutics reported a Q3 beat, raising full-year Briumvi sales guidance by $7.5 million. Key updates expected in early 2025 include Q4 sales and trial results for subcutaneous Briumvi.
Why It Matters - TG Therapeutics' Q3 performance and raised guidance indicate stable growth potential for Briumvi, setting the stage for future developments that could impact stock valuations and investor sentiment.
Tue, 05 Nov 2024
Sentiment - POSITIVE
Source - Investors Business Daily
Summary - Investors are encouraged to explore stocks beyond Nvidia, Amazon, and Tesla to identify opportunities for significant earnings growth.
Why It Matters - The exclusion of major stocks like Nvidia, Amazon, and Tesla suggests emerging opportunities elsewhere, indicating potential for higher returns in overlooked sectors.
Mon, 04 Nov 2024
Sentiment - NEGATIVE
Source - Investors Business Daily
Summary - TG Therapeutics stock declined after third-quarter results showed a profit miss, despite exceeding sales expectations for its multiple sclerosis treatment.
Why It Matters - TG Therapeutics' stock drop signals investor disappointment over profit misses despite strong sales, indicating potential volatility and caution in future earnings projections.
Mon, 04 Nov 2024
Sentiment - NEUTRAL
Source - Seeking Alpha
Summary - TG Therapeutics, Inc. (NASDAQ:TGTX) will hold its Q3 2024 earnings conference call on November 4, 2024, at 8:30 AM ET, featuring key executives and analysts from major financial firms.
Why It Matters - The Q3 earnings call date indicates upcoming financial performance insights for TG Therapeutics, impacting stock valuation and investor sentiment.
Mon, 04 Nov 2024
Sentiment - NEGATIVE
Source - Seeking Alpha
Summary - TG Therapeutics' Q3 earnings missed EPS expectations due to higher costs, despite Briumvi's $83.3 million revenue (15% QoQ growth). Full-year revenue guidance is raised to $300-305 million.
Why It Matters - TG Therapeutics missed EPS expectations, signaling potential cash flow issues. However, Briumvi's revenue growth and raised guidance reflect confidence in its market position, offsetting some concerns.
The information that Ticker Nerd provides is general in nature as it has been prepared without taking account of your objectives, financial situation or needs. It is not intended as legal, financial or investment advice and should not be construed or relied on as such. Ticker Nerd is for information purposes only. Ticker Nerd is not responsible for any damages or losses that may occur as a result of reliance on this information. Before making any commitment of a legal or financial nature you should seek advice from a qualified and registered legal practitioner or financial or investment adviser. All content, group, messaging, tweets, newsletter, article, and email created by Ticker Nerd is intended for educational and information purposes only, is not financial, investment, legal or tax advice, and is a restatement, summary or extract of other data and research reports that are widely distributed from sources such as, but not limited to, Bloomberg, Market Watch, Wall Street Journal, Google Finance, and Yahoo Finance. Ticker Nerd is not a registered financial, investment, legal or tax advisor and is not liable for any financial loss you may incur acting on any information provided by Ticker Nerd. By registering, you agree not to hold Ticker Nerd liable at any time or under any circumstances for your decisions, actions, or results.
